EMA Withdrawn: Budesonide/Formoterol Teva Pharma B.V. (Budesonide;formoterol) — Teva Pharma B.V.

View source ↗

Summary

The EMA withdrew the Budesonide/Formoterol Teva Pharma B.V. product, a combination therapy for asthma, from its marketing authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Budesonide/Formoterol Teva Pharma B.V. (budesonide;formoterol)

Snippet

Status: Withdrawn. Therapeutic area: Asthma. MAH: Teva Pharma B.V.. Decision date: 16/12/2016